Catalog No.
Product Name
Application
Product Information
Citations
-
cAMP Analogue
8-CPT-cAMP-AM is a membrane-permeant analogue of cyclic adenosine monophosphate (cAMP) that acts as an activator of cAMP- and cGMP-dependent protein kinases. It also stimulates exchange protein directly activated by cAMP (Epac), making it a valuable tool for investigating cAMP signaling pathways. This compound is useful in research applications studying cellular processes influenced by cAMP, such as cell proliferation, differentiation, and effects on various physiological responses. -
pan-KRAS Inhibitor
pan-KRAS-IN-6 is a highly potent pan-KRAS inhibitor, exhibiting IC50 values of 9.79 nM for Kras G12D and 6.03 nM for Kras G12V. This compound effectively targets KRAS mutant forms associated with various cancers, making it a valuable tool for studying KRAS signaling pathways and evaluating therapeutic strategies in KRAS-driven tumors. Its specificity and efficacy position it as a key reagent in cancer research and drug discovery efforts targeting KRAS-related malignancies. -
KRAS G12C inhibitor
KRAS G12C inhibitor 21 is a selective inhibitor targeting the KRAS G12C oncogene. It effectively disrupts downstream signaling pathways associated with cell proliferation and survival in KRAS-driven malignancies. This compound is primarily utilized in cancer research to explore therapeutic strategies for malignancies harboring KRAS G12C mutations. -
Anti-cancer Agent
KRAS G12C inhibitor 37 is a selective inhibitor targeting the KRAS G12C mutation, a key driver in various cancers. This compound displays significant efficacy in disrupting KRAS-mediated signaling pathways, thus impeding tumor growth and proliferation. KRAS G12C inhibitor 37 is intended for research applications focused on elucidating the therapeutic potential in KRAS G12C-driven malignancies. -
pan-KRAS Inhibitor
pan-KRAS-IN-15 is a pan-KRAS inhibitor that targets multiple KRAS mutant variants. This compound exhibits potent inhibitory activity against KRAS-driven signaling pathways, making it valuable for studying the mechanisms of KRAS-related cancers. It is particularly relevant for research focused on pancreatic cancer, providing insights into therapeutic strategies and disease progression. -
KRAS Inhibitor
KRAS Inhibitor-22 is a selective inhibitor of the K-Ras protein, specifically targeting the Kras 4B(G12D) and Kras 4B(G12C) mutant forms. This compound exhibits potent anti-cancer activity, making it a valuable tool in cancer research aimed at understanding K-Ras-driven malignancies. Its application can aid in elucidating the role of K-Ras in cancer progression and therapeutic resistance. -
KRAS G12C Inhibitor
KRAS inhibitor-13 is a selective inhibitor targeting the mutant KRAS G12C protein, demonstrating its potency with an IC50 value of 0.883 µM. This compound effectively inhibits phosphorylated ERK (p-ERK) in cell lines, showing IC50s of 5.9 µM in MIA PaCA-2 cells and >100 µM in A549 cells. KRAS inhibitor-13 is poised for research applications focused on pancreatic, colorectal, and lung cancers, providing insights into therapeutic strategies against KRAS-driven malignancies. -
KRAS G12C Inhibitor
KRAS G12C Inhibitor 44 is a potent and orally bioavailable inhibitor targeting the KRAS G12C mutation. This compound exhibits significant anti-proliferative activity, with IC50 values of 0.016 µM in MIA PaCA-2 cells and 0.028 µM in H358 cells. Additionally, KRAS G12C Inhibitor 44 demonstrates antitumor effects in vivo, making it a valuable tool for cancer research focusing on KRAS-driven malignancies. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 52 is a selective inhibitor targeting the KRAS G12C mutant protein. This compound effectively disrupts KRAS signaling pathways, thereby inhibiting cell proliferation and survival in KRAS G12C-driven cancers. Its research applications include studies on cancer biology, drug development, and understanding resistance mechanisms in targeted therapies. -
KRAS G12C Inhibitor
KRAS inhibitor-12 is a potent inhibitor specifically targeting the KRAS G12C mutation, exhibiting an IC50 of 0.537 µM. This compound demonstrates effective inhibition of phosphorylated ERK in MIA PaCA-2 and A549 cells, with IC50 values of 1.3 µM and 3.7 µM, respectively. KRAS inhibitor-12 is a valuable tool for investigating therapeutic strategies in pancreatic, colorectal, and lung cancers. -
Anti-cancer Agent
KRAS G12D inhibitor 12 specifically targets the KRAS G12D mutation, a critical player in cellular signaling pathways associated with tumorigenesis. This compound exhibits potent anti-cancer activity, making it a valuable tool for researchers investigating KRAS G12D-mediated cancers. Its application includes evaluating therapeutic strategies and understanding the molecular mechanisms of oncogenic signaling in various cancer types. -
KRAS G12C Inhibitor
KRAS G12C Inhibitor 46 is a potent inhibitor targeting the KRAS G12C mutation, an essential driver in various cancers. This compound effectively blocks the aberrant signaling pathways associated with KRAS G12C, leading to reduced proliferation and enhanced apoptosis in cancer cells harboring this mutation. It is primarily utilized in cancer research, particularly for exploring therapeutic strategies targeting KRAS-dependent tumors. -
KRAS Inhibitor
KRAS Inhibitor-23 is a selective inhibitor targeting KRAS, a critical protein involved in cell signaling pathways that regulate cell growth and differentiation. This compound demonstrates significant biological activity by effectively disrupting KRAS-mediated oncogenic signaling, making it a valuable tool in cancer research. Its application spans the investigation of KRAS mutations and their role in tumor progression, providing insights into potential therapeutic strategies for KRAS-driven malignancies. -
KRASG12D Inhibitor
KRASG12D-IN-5 is a potent inhibitor targeting the KRAS(G12D) mutation, exhibiting an IC50 of 11 nM. This compound demonstrates significant anticancer activity, displaying low cytotoxicity against various cell lines, including 10.37 μM for BxPC-3 (wild type), 0.76 μM for KRAS mutant AsPC-1 (G12D), and 0.3 μM for MIAPaCa-2 (G12C). KRASG12D-IN-5 is valuable for cancer research, particularly in the context of lung, pancreatic, and colorectal cancers. -
Mutant KRAS Inhibitor
KRAS-IN-48 free base is a highly selective inhibitor targeting mutant KRAS, specifically KRAS G12D and KRAS G12V, with Kd values of 2.58 nM and 5.49 μM, respectively. This compound effectively reduces pERK expression in KRAS-mutant cells, exhibiting IC50 values of 1.1 μM and 1.51 μM for KRAS G12D and G12V mutations. KRAS-IN-48 free base serves as a valuable tool in cancer research, contributing to the understanding of KRAS-driven malignancies. -
KRAS G12D Inhibitor
KRAS G12D inhibitor 24 is a potent inhibitor of the KRAS G12D mutant, exhibiting an IC50 of 0.004 μM. This compound demonstrates significant oral bioactivity, making it suitable for in vivo studies. Its primary applications include exploring therapeutic avenues in cancer research, specifically for tumors driven by KRAS G12D mutations. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 58 specifically targets the KRAS G12C mutant protein, effectively disrupting its activity and downstream signaling pathways. This compound demonstrates potent antitumor efficacy, making it a valuable tool for studying KRAS-driven malignancies. Its applications extend to cancer research, particularly in the development and testing of novel therapeutic strategies for treating KRAS G12C-dependent tumors. -
KRAS Inhibitor
pan-KRAS-IN-13 is a potent KRAS inhibitor that targets mutant forms of the KRAS protein, demonstrating IC50 values of 2.75 nM and 2.89 nM for G12D and G12V mutations, respectively. This compound is valuable for research applications aimed at understanding KRAS-driven cancers and evaluating therapeutic strategies to inhibit KRAS signaling pathways. Its high specificity and efficacy make it a critical tool for the study of oncogenic mutations associated with various malignancies. -
KRAS G12D Inhibitor
RNK08954 is a KRAS G12D inhibitor targeting the KRAS oncogene mutation commonly found in various cancers. This compound demonstrates the ability to impede KRAS-driven cellular signaling pathways, making it a valuable tool for investigating the role of KRAS G12D in tumorigenesis. RNK08954 is suitable for research applications focused on cancer biology and therapeutic development against KRAS-mutant tumors. -
cAMP Analogue
8-Br-2'-O-Me-cAMP is a synthetic analog of cyclic AMP (cAMP) that selectively activates exchange factors activated by cAMP (Epac) without stimulating protein kinase A (PKA). This unique property makes it a valuable tool for investigating cAMP-mediated signaling pathways. It is particularly relevant in studies related to cardiovascular diseases, facilitating the exploration of Epac's role in cardiac function and pathology. -
Anti-cancer Agent
KRAS G12C inhibitor 40 is a selective inhibitor targeting the KRAS G12C mutation, a critical driver in various cancers. This compound disrupts the aberrant signaling pathways associated with KRAS G12C, demonstrating significant anti-cancer activity. KRAS G12C inhibitor 40 is valuable for research into the mechanisms of KRAS G12C-mediated tumorigenesis and for the development of targeted cancer therapies. -
KRAS G12C Inhibitor
ARS-2102 is a potent covalent inhibitor of the KRAS G12C mutation, a key driver in various cancers. By selectively targeting this mutated oncogene, ARS-2102 exhibits significant anti-tumor activity, making it a valuable tool for cancer research. Its application is particularly relevant in studies focused on therapeutic strategies for KRAS-driven malignancies. -
Rce1 Inhibitor
NSC 1008 is a selective inhibitor of Ras converting enzyme 1 (Rce1), exhibiting an in vitro IC50 of 8.9 μM in human cells. This compound demonstrates specificity for Rce1, showing minimal inhibitory effects on human Ste24 and farnesyltransferase. NSC 1008 has low cellular toxicity and effectively induces mislocalization of EGFP-Ras from the plasma membrane in cancer cells. It serves as a valuable reagent for cancer research, facilitating studies on Rce1's role in oncogenic signaling pathways. -
KRas Inhibitor
Spiclomazine hydrochloride is a KRas inhibitor recognized for its dual role as an antipsychotic and antitumor agent. This compound effectively induces apoptosis in cancer cells, making it a valuable tool in cancer research. Its action on KRas allows for exploration into the mechanisms of tumorigenesis and potential therapeutic strategies targeting KRas-driven malignancies. -
RAS Activator
RAS Activator Compound 1 is a specific activator targeting the guanine nucleotide exchange factor, son of sevenless homologue 1 (SOS1). This compound effectively facilitates the nucleotide exchange process, leading to increased levels of active RAS-GTP in HeLa cells. RAS Activator Compound 1 is valuable for research focused on RAS-driven tumors, providing insights into the mechanisms of RAS activation and its role in cancer biology. -
Anti-cancer Agent
KRAS G12C inhibitor 39 is a selective inhibitor targeting the KRAS G12C mutation, which is frequently associated with various cancers. This compound demonstrates significant anti-tumor activity by interfering with KRAS signaling pathways, making it a valuable tool for research into KRAS G12C-mediated oncogenesis. Its application extends to studies aimed at understanding the efficacy of targeted therapies in KRAS-driven malignancies. -
KRAS Inhibitor
AMG410 diTFA is a selective pan-KRAS inhibitor targeting various KRAS mutations, including G12D, G12V, and G13D, with IC50 values ranging from 1 to 4 nM. It exhibits over 100-fold selectivity against HRAS and NRAS and acts as a dual inhibitor of GTP-bound and GDP-bound states (Kd(GDP) of 1 nM; Kd(GTP) of 22 nM). AMG410 diTFA effectively disrupts KRAS signaling irrespective of cycling state and inhibits proliferation in wild-type KRAS-amplified tumor cells. This compound is valuable for research on colorectal, pancreatic, and lung cancers. -
KRAS G12C Inhibitor
KRAS G12C Inhibitor 47 is a selective inhibitor targeting the KRAS G12C mutation, exhibiting an IC50 of 0.172 µM. It effectively inhibits p-ERK signaling, with IC50 values of 0.046 µM in MIA PaCA-2 cells and 69.8 µM in A549 cells. This compound is a valuable tool for researching therapeutic strategies in pancreatic, colorectal, and lung cancers. -
KRAS G12C Inhibitor
KRAS Inhibitor-15 is a selective inhibitor targeting the KRAS G12C mutation, exhibiting a potent IC50 of 0.954 µM. This compound demonstrates effective inhibition of phosphorylated ERK (p-ERK) with IC50 values of 2.03 µM in MIA PaCA-2 cells and >33.3 µM in A549 cells. KRAS Inhibitor-15 is suitable for investigating therapeutic strategies in pancreatic, colorectal, and lung cancers, contributing to the understanding of KRAS-driven tumorigenesis. -
KRAS G12D Inhibitor
KRAS G12D-IN-32 is a selective inhibitor of the KRAS G12D mutant protein, which plays a critical role in various oncogenic pathways. This compound is instrumental for investigating the molecular mechanisms underlying adenocarcinoma, colorectal cancer, and non-small cell lung cancer. Researchers can employ KRAS G12D-IN-32 to explore therapeutic strategies targeting KRAS mutations and to evaluate potential treatment responses in cancer models. -
Epac Activator
8-pCPT-2′-O-Me-cAMP is a selective activator of exchange proteins activated by cAMP (Epac), specifically targeting Epac1 with an EC50 of 2.2 μM. This compound does not activate protein kinase A (PKA) with an EC50 greater than 10 μM. 8-pCPT-2′-O-Me-cAMP effectively stimulates Epac-mediated Ca2+ release in pancreatic β-cells in vitro, and it plays a role as a Rap1 activator. Additionally, it enhances the barrier function of retinal pigment epithelium against choroidal endothelial cell invasion, potentially providing insights into therapeutic mechanisms for macular degeneration. -
KRASG12C Inhibitor
KRASG12C IN-17 is an orally active covalent inhibitor targeting the KRASG12C mutation. It demonstrates potent inhibitory effects on KRASG12C-mutant cancer cell lines, with IC50 values of 0.7 nM in NCI-H23 and 0.5 nM in NCI-H358. This compound irreversibly binds to KRASG12C, achieving over 96% modification efficiency in both GDP-bound and GMPPNP-bound states. KRASG12C IN-17 is valuable for research focused on KRAS-driven malignancies, particularly in the context of colorectal cancer. -
Anti-cancer Agent
KRAS G12C inhibitor 35 is a selective inhibitor targeting the KRAS G12C mutation, a driver mutation frequently associated with various cancers. This compound effectively disrupts KRAS signaling pathways, leading to inhibition of tumor cell proliferation. It serves as a valuable tool for research into KRAS G12C-mediated oncogenesis and therapeutic strategies in cancer treatment. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 30 is a selective inhibitor targeting the KRAS G12C mutation. This compound demonstrates significant anti-tumor activity by disrupting the downstream signaling pathways associated with oncogenic KRAS. It is primarily utilized in cancer research, particularly in studies focused on therapies for KRAS-driven malignancies. -
KRAS Dimerizing Agent
PPI stabilizer-1 is a KRAS dimerizing agent that effectively promotes the dimerization of KRAS with a dissociation constant (KD) of 3.8 µM. This compound has the ability to co-crystallize with GCP-KRASG12D, facilitating structural studies and elucidating the role of KRAS in cellular signaling. PPI stabilizer-1 is valuable for researching KRAS-driven cancers, providing insights into therapeutic strategies targeting this critical pathway. -
KRAS Ligand
KRAS Ligand 3 is a target-binding ligand for KRAS that interacts with the KRAS inhibitor, enhancing its efficacy. This compound demonstrates synergistic effects in tumor growth inhibition, making it a valuable tool for research in cancer biology and therapeutic development. Its application in studying KRAS-related signaling pathways can provide insights into tumorigenesis and potential treatment strategies. -
K-Ras Antagonist
K-Ras-IN-2 is a selective antagonist of the K-Ras protein. It has demonstrated significant biological activity in inhibiting K-Ras-driven signaling pathways, making it a valuable tool for researchers studying tumor biology and oncogenic signaling. This compound is particularly useful in cancer research applications focused on K-Ras-related malignancies. -
KRAS Inhibitor
COTI-219 is an orally active inhibitor of the KRAS protein, targeting its role in oncogenic signaling pathways. This compound exhibits significant antitumor activity, making it a valuable tool for cancer research. COTI-219 is utilized in studies aimed at understanding KRAS-related signaling mechanisms and evaluating therapeutic strategies for KRAS-driven tumors. -
KRAS G12C Inhibitor
KRAS G12C Inhibitor 48 is a potent inhibitor targeting the KRAS G12C mutation, with an IC50 of 639.91 nM. This compound demonstrates significant anti-proliferative activity in various cancer cell lines, exhibiting IC50 values of 0.796 µM in H358, 6.33 µM in H23, and 16.14 µM in A549 cells. It serves as a valuable tool for research into KRAS-driven malignancies and therapeutic strategies targeting mutant KRAS. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 59 selectively targets the KRAS G12C mutant protein, inhibiting its downstream signaling pathways. This compound exhibits significant anticancer activity, making it a valuable tool for research focused on KRAS-driven malignancies. It holds potential for further exploration in therapeutic applications against cancers harboring the KRAS G12C mutation. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 23 is a selective inhibitor targeting the KRAS G12C mutation. It effectively inhibits H358 cells with an IC50 value of 491 nM, demonstrating its potential in cancer research. This compound is primarily utilized in studies focused on KRAS-driven cancers for therapeutic development and efficacy evaluation. -
KRAS G12C Inhibitor
KRAS G12C Inhibitor 25 primarily targets the KRAS G12C mutant by inhibiting the SOS1-assisted GDP/GTP exchange activity, demonstrating an IC50 of 0.48 nM. This compound has potential applications in therapeutic research aimed at KRAS-driven cancers, providing a valuable tool for studying the role of KRAS mutations in tumorigenesis and evaluating potential treatment strategies. -
KRAS G12D Inhibitor
KRAS G12D Inhibitor 15 is a selective inhibitor targeting the KRAS G12D mutation, a critical player in various cancer pathways. This compound demonstrates significant potential in studies related to cancer progression and metastasis. Additionally, KRAS G12D Inhibitor 15 features an alkyne moiety, enabling its use in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions, making it a valuable tool for chemical biology applications. -
Ra Inhibitor
pan-KRAS-IN-17 is a potent inhibitor targeting pan-KRAS. This compound effectively disrupts KRAS signaling pathways, demonstrating significant activity in various cancer models characterized by KRAS mutations. It is a valuable tool for research into KRAS-driven malignancies and for investigating therapeutic approaches aimed at inhibiting malignant cell proliferation and survival. -
Anti-cancer Agent
KRAS G12D inhibitor 11 is a potent inhibitor targeting the KRAS G12D mutation, a critical driver of various cancers. This compound interferes with the signaling pathways mediated by the Ras family of proteins, which are essential for cellular proliferation and survival. KRAS G12D inhibitor 11 is applicable in research focused on KRAS G12D-mediated oncogenesis and therapeutic development for related malignancies. -
Ras Inhibitor
StRIP16 is a bioavailable analogue of StRIP3 that functions as a Ras inhibitor. This double-stapled peptide exhibits high specificity for Rab8a GTPase, with a dissociation constant (Kd) of 12.7 μM. StRIP16 is utilized in research to investigate the role of Rab8a in cellular signaling pathways and its implications in various cancer models. -
Ra Inhibitor
ISIS 2503 is a 20-mer antisense oligonucleotide specifically designed to inhibit the expression of Ha-Ras. By targeting the mRNA of Ha-Ras, ISIS 2503 effectively reduces its protein levels, thereby modulating downstream signaling pathways associated with cell proliferation and survival. This reagent is valuable for research applications focused on cancer biology and the study of oncogenic signaling mechanisms. -
pan-KRAS Inhibitor
pan-KRAS-IN-3 is a pan-KRAS inhibitor designed to target and inhibit KRAS signaling pathways, which are commonly implicated in various cancers. This compound serves as a useful tool for cancer research by effectively blocking KRAS activity, thereby offering insights into tumor biology and potential therapeutic strategies. Additionally, pan-KRAS-IN-3 features an alkyne group enabling its participation in copper-catalyzed azide-alkyne cycloaddition (CuAAc), facilitating the development of novel chemical probes and conjugates in experimental studies. -
KRAS G12D inhibitor
KRAS G12D inhibitor 19 is a selective inhibitor targeting the KRAS G12D mutant protein, which plays a pivotal role in driving oncogenic signaling pathways in various cancers. This compound exhibits significant anti-proliferative activity against KRAS G12D-driven tumor cell lines. It serves as a valuable tool in cancer research, particularly for studying the efficacy of KRAS-targeted therapies and understanding the mechanistic pathways involved in KRAS-related malignancies. -
Rho GTPase Inhibitor
Rho GTPase Inhibitor 1 is a selective inhibitor targeting Rho GTPases, with demonstrated high affinity for Cdc42, Rac1, and RhoA, exhibiting KDs of 151, 352, and 232 μM, respectively. This compound effectively reduces cell migration in glioma cell lines, highlighting its potential utility in cancer research and therapeutic development. Its role in modulating Rho GTPase signaling makes it a valuable tool for investigating cellular processes such as motility and invasion.
